ObsEva and Kissei Pharmaceutical announce global agreement to develop and commercialize KLH-2109 for the treatment of endometriosis

ObsEva and Kissei Pharmaceutical announce global agreement to develop and commercialize KLH-2109 for the treatment of endometriosis

ObsEva and Kissei Pharmaceutical Co., Ltd. (“Kissei”) today announced that they have entered into a collaboration agreement to develop and commercialize KLH-2109 for the treatment of endometriosis and other potential indications. KLH-2109 is a novel, oral gonadotropin-releasing hormone (GnRH) antagonist, for which three Phase 2a studies have been completed in endometriosis in Japan. Under the terms of the agreement, ObsEva will acquire the exclusive rights to develop and commercialize KLH-2109 worldwide, excluding Asia. Both companies will collaborate in parallel on the development of KLH-2109, represented in ObsEva’s pipeline as OBE2109. The financial terms of the deal are not being disclosed.

Source: ObsEva

Plus

Leave a reply